Fig. 3From: Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The NetherlandsTornado diagram presenting parameters with most influence on incremental QALYs an costs Key: The lower case presents the outcome for the 2.5% CI of the distribution. The higher case presents the outcome of the 97.5% CI of the distribution. CKD chronic kidney diseas, CV cardiovascular event; FIN finerenone; HR hazard ratio, SoC standard of careBack to article page